TransMedics Group, Inc. $TMDX Shares Purchased by Fred Alger Management LLC

Fred Alger Management LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 303.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,741 shares of the company’s stock after buying an additional 113,408 shares during the period. Fred Alger Management LLC’s holdings in TransMedics Group were worth $16,913,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Canada Pension Plan Investment Board boosted its stake in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares during the period. US Bancorp DE increased its position in shares of TransMedics Group by 24.2% during the third quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after acquiring an additional 104 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of TransMedics Group by 24.5% in the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after acquiring an additional 108 shares during the period. State of Wyoming raised its stake in shares of TransMedics Group by 20.9% in the 3rd quarter. State of Wyoming now owns 683 shares of the company’s stock valued at $77,000 after acquiring an additional 118 shares during the period. Finally, TD Waterhouse Canada Inc. lifted its holdings in shares of TransMedics Group by 26.5% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 601 shares of the company’s stock worth $69,000 after acquiring an additional 126 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $124.70 on Tuesday. The firm has a market capitalization of $4.28 billion, a price-to-earnings ratio of 25.45 and a beta of 1.98. The firm’s fifty day simple moving average is $135.89 and its 200-day simple moving average is $127.40. TransMedics Group, Inc. has a twelve month low of $62.23 and a twelve month high of $156.00. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06.

Analyst Ratings Changes

TMDX has been the subject of a number of research analyst reports. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC boosted their target price on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus upped their price target on TransMedics Group from $115.00 to $130.00 and gave the stock a “hold” rating in a research note on Monday, March 9th. Oppenheimer raised their price target on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, TD Cowen reaffirmed a “buy” rating on shares of TransMedics Group in a research note on Monday. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $152.33.

Insider Transactions at TransMedics Group

In other news, insider Nicholas Corcoran sold 2,966 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $412,629.92. Following the completion of the transaction, the insider directly owned 29,831 shares of the company’s stock, valued at approximately $4,150,088.72. This represents a 9.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Stephanie Lovell sold 1,193 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the transaction, the director owned 2,866 shares in the company, valued at approximately $428,810.92. The trade was a 29.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,205 shares of company stock valued at $2,353,002 over the last ninety days. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.